Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30395295 | 0.79 | TSHR (0.31) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL830114 | 0.79 | TSHR (0.33) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL27565357 | 0.76 | TSHR (0.31) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL27778400 | 0.74 | — | — | |
| SCHEMBL27471194 | 0.74 | — | — | |
| SCHEMBL7174885 | 0.73 | KDM4E (0.33) | — | |
| SCHEMBL1236956 | 0.72 | TSHR (0.33) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL9957230 | 0.71 | TSHR (0.34) | TSHRMAPK1HSD17B10TDP1 | |
| Hydrochloric Acid SCHEMBL5502358 | 0.71 | THRB (0.34) | TSHRMAPK1HSD17B10TDP1 | |
| Hydrochloric Acid SCHEMBL17667153 | 0.71 | THRB (0.34) | TSHRMAPK1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143405-B2 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2077719-B1 | PIPERIDINE AND PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2010-02-18 | — | — | US | disclosed |
| EP-2077719-A2 | PIPERIDINE AND PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck and Co., Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008036316-A2 | PIPERIDINE AND PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, PSEN1 | TSHR 4743/4885MAPK1 3119/4885HSD17B10 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.